

CSF Pleocytosis Reference Ranges

Inability to obtain CSF in ED

- Administer antibiotics within 60 minutes, should not be held for severely ill patients pending LP
- Rapid CSF Bacterial PCR can be sent on pre-treated CSF that demonstrates pleocytosis

CSF Pleocytosis can vary by age, listed values below should be used in conjunction with cilnical judement and patient characterstics

< 28 days: 15 cells/mm³
 29-60 days: 9 cells/mm³

Additional reference ranges for healthy newborns

Table 6-12 Hematologic and Chemical Characteristics of Cerebrospinal Fluid in Healthy Newborns: Results of Selected Studies

Study (year)	No. of Patients	Age (days)	White Blood Cells* (mm³)	Neutrophils* (mm³)	Glucose* (mg/dL)	Protein* (mg/dL)
Naidoo ⁸¹³ (1968)	135	1	12 (0-42)	7 (0-26)	48 (38-64)	73 (40-148)
	20	7	3 (0-9)	2 (0-5)	55 (48-62)	47 (27-65)
Sarff ⁴⁸⁸ (1976)	87	Most < 7	8.2 ± 7.1 , median 5 (0-32)	61	52 (34-119)	90 (20-170)
Bonadio ⁵⁶⁵ (1992)	35	0-4 wk	11.0 ± 10.4 , median 8.5	0.4 ± 1.4, median 0.15	46 ± 10.3	84 ± 45.1
	40	4-8 wk	7.1 ± 9.2 , median 4.5	0.2 ± 0.4 , median 0	46 ± 10.0	59 ± 25.3
Ahmed ⁵⁶⁶ (1996)	108	0-30	7.3 ± 13.9 , median 4	0.8 ± 6.2 , median 0	51.2 ± 12.9	64.2 ± 24.2

Data from Ahmed A, Hickey S, Ehrett S, et al: Cerebrospinal fluid values in the term neonate, Pediatr Infect Dis J 15:298, 1996.

Nizet, V. and Klein, J. ed., 2016. Bacterial Sepsis and Meningitis. In: Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant, 8th ed.

TABLE 2 CSF Values in Febrile Infants Without Evidence of UTI, IBI, HSV, Enterovirus, or Traumatic CSF

	Age, d	n	Mean	Median	Range
WBCs per mm ³	1–28	278	6.1	5.0	0-18
	29-60	318	3.1	3.0	0-8.5
Protein mg/dL	1-28	278	75.4	73.0	15.8-131.0
	29-60	318	58.9	54.0	5.5-105.5
Glucose	1-28	278	45.3	46.0	30.0-61.0
Glucose	29-60	318	48.0	48.0	20.6-65.5
RBCs per mm ³	1–28	278	95.5	5.5	0-236
RBCs per mm ³	29-60	318	75.5	2.0	0-64.5

Statistical outliers were removed. Other studies reveal slightly different ranges. Local laboratory tests may provide slightly different upper limits of normal. Adapted from Byington CL, Kendrick J, Sheng X. Normative cerebrospinal fluid profiles in febrile infants. J Pediatr. 2011;158(1):130–134.

^{*}Expressed as mean with range (number in parentheses) or ± standard deviation unless otherwise specified.

HSV should be considered when there is:

- Maternal history of genital HSV lesions or fever from 48 hours before to 48 hours after delivery
- Infants with vesicles, seizures, hypothermia, mucous membrane ulcers
- •CSF pleocytosis in the absence of a positive Gram stain result
- Consider in the presence of leukopenia, thrombocytopenia, or elevated alanine aminotransferase levels.

Return to Pathway

For most current ICN dosing card guidelines: http://carelinks.ucsfmedctr.org//clinical_guidelines.asp

Edition 7; 3/2019 Approved by ICN Joint Practice 3-2019, BCH Med Committee 3-2019 Approved by P&T 4-2019

Neonatal Drug Guidelines UCSF Benioff Children's Hospital 2019 – 2021

Drug		Dose	2021	Interval	Mode	
				<u>iiitei vai</u>	Mode	
Antibacteria	Antibacterials/Antifungals/Antivirals:					
Acyclovir		20 mg/kg/dose		q 8 hours	IV	
Amphotericin	Conventional (F		1 mg/kg/dose	q 24 hours	IV	
	Liposomal (Am		5 mg/kg/dose	q 24 hours	IV	
Ampicillin	Meningitis	100 mg/kg/dose	е	see Interval A	IV	
		50 mg/kg/dose		see Interval A	IV	
Azithromycin	(pertussis)	10 mg/kg/dose		q 24 hours x 5 days	IV/PO	
Cefazolin		25 mg/kg/dose		see Interval B	IV	
Cefepime		50 mg/kg/dose	B.A	q 12 hours	IV	
0 ()		50 // / /	Meningitis	q 8 hours	IV	
Cefotaxime		50 mg/kg/dose	NA in iti-	see Interval A	IV	
0 - ffui	Adam barasasida		Meningitis	see Interval C	IV	
Ceftriaxone				rected GA and > 14 day		
				ontaining IV solutions w		
Ceftazidime	cennaxone mei		armacisi ior veri	ification of criteria and d see Interval B	IV	
Clindamycin		50 mg/kg/dose see Column E		g 8 hours	IV	
Fluconazole	Treatment		a v1 than 12 ma	g/kg/dose q 24 hours	IV/PO	
Fluconazole	Prophylaxis	6 mg/kg/dose:	g x 1, then 12 mg	grkyruose y 24 nours	IV/FO	
	Гторпуталь		GA & ≤ 28 d PN	MA: α 72 hours	IV/PO	
			GA & 3 28 d P		17/1-0	
Gentamicin and	1 Tohramycin		ttom for dosing a		IV	
Meropenem	20 mg/kg/dose		for meningitis/p		1 V	
Moroponom	20 mg/ng/4000		. & < 14 days Pl		IV	
			or ≥ 14 days P		IV	
Metronidazole				/kg/dose q 12 hours		
LOAD 15 m	a/ka x1.	34-40 weeks co	orr. GA: 7.5 mg	/kg/dose q 8 hours	IV	
				/kg/dose q 8 hours		
Nafcillin	·	50 mg/kg/dose	ŭ	see Interval A	IV	
PenicillinG (aq)	congenital syph	ilis: 50,000 unit	s/kg/dose x 10 c	days see Interval A	IV	
Piperacillin/tazo				ose see Interval C	IV	
Pseudomonas: 100 mg piperacillin/kg/dose						
TMP/SMX (Bad	ctrim/Septra)			corrected Gestational Ag	ge	
Vancomycin			GA: 10 mg/kg/dd			
		> 29 wks corr. (GA: 15 mg/kg/do	ose see Interval D	IV	

Corrected Gestational age (weeks)	Postnatal age (days)	Interval A	Interval B	Interval C	Interval D	Column E
< 20	0 – 28	q 12°	q 12°	q 12°	see	1 mg/kg/doso
≤ 29	> 28	9 8 p	9 8 p	q 8°	drug entry	4 mg/kg/dose
30 – 36	0 – 14	q 12°	q 12°	q 8°	q 12°	6 mg/kg/dose
30 – 36	> 14	q 8°	q 8°	q 6°	q 8°	
37 – 44	0 – 7	q 12°	q 12°	q 8°	q 12°	8 mg/kg/dose
37 – 44	> 7	q 8°	q 8°	q 6°	q 8°	
<u>≥</u> 45	All	q 6°	q 8°	q 6°	q 6°	10 mg/kg/dose

Chart below is for dosing of Gentamicin & Tobramycin ONLY

BIRTH to 1 MONTH

Gestational Age (weeks)	Dose	Interval
≤ 28	3.5 mg/kg/dose	q 36 hours
29 – 34	3.5 mg/kg/dose	q 24 hours
≥ 35	5 mg/kg/dose	q 24 hours (q36h for HIE or significant asphyxia)

< 35 week GA: Order Peak/Trough with 4th dose
≥ 35 week GA: Order Trough ONLY with 4th dose
(for HIE or significant asphyxia, P/T with 3rd dose)

> 1 MONTH POSTNATAL

> 1 MONTH POSTNATAL						
Corrected Gestational Age (weeks)	Dose	Interval				
< 35	2.5	q 12 hours				
<u>≥</u> 35	mg/kg/dose	q 8 hours^				
Corrected Gestational Age (weeks) < 35 ≥ 35	Dose	q 12 hours				

Discharge Checklist

- Are the parents comfortable with monitoring the child at home
- Do parents have reliable means of receiving communication from hospital
- Can culture results be followed daily by hospital staff
- Can patient follow up with PCP within 24 hours
- Can patient tolerate oral antibiotics, if indicated

If NO to ANY: Admit

Return to pathway

Validity of using the UA as a screening tool before sending a urine culture

- 1. Schroeder AR, Chang PW, Shen MW, Biondi EA, Greenhow TL. Diagnostic accuracy of the urinalysis for urinary tract infection in infants <3 months of age. *Pediatrics*. 2015;135(6):965-971
- 2. Tzimenatos L, Mahajan P, Dayan PS, et al. Accuracy of the urinalysis for urinary tract infections in febrile infants 60 days and younger. *Pediatrics*. 2018;141(2):e20173068

Use of inflammatory markers for risk stratification

- 1. Aronson PL, Shabanova V, Shapiro ED, et al. A prediction model to identify febrile infants ≤60 days at low risk of invasive bacterial infection. *Pediatrics*. 2019;144(1):e20183604
- 2. Gomez B, Mintegi S, Bressan S, et al. Validation of the "Step-by-Step" approach in the management of young febrile infants. *Pediatrics*. 2016;138(2):e20154381. doi: 10.1542/peds.2015-4381. Epub 2016 Jul 5
- 3. Kuppermann N, Dayan PS, Levine DA, et al. A clinical prediction rule to identify febrile infants 60 days and younger at low risk for serious bacterial infections. *JAMA Pediatr*. 2019;173(4):342-35160
- 4. Milcent K, Faesch S, Gras-Le Guen C, et al. Use of procalcitonin assays to predict serious bacterial infection in young febrile infants. *JAMA Pediatr.* 2016;170(1):62-69

Use of selective lumbar punctures in febrile infants with positive UAs

- 1. Burstein B, Sabhaney V, Bone JN, Doan Q, Mansouri FF, Meckler GD. Prevalence of bacterial meningitis among febrile infants aged 29-60 days with positive urinalysis results: a systematic review and meta-analysis. *JAMA Netw Open*. 2021 May 3;4(5):e214544
- 2. Velasco R, Lejarzegi A, Gomez B, et al. Febrile young infants with abnormal urine dipstick at low risk of invasive bacterial infection. *Arch Dis Child*. 2020 Nov 27:archdischild-2020-320468
- 3. Wang ME, Biondi EA, McCulloh RJ, et al. Testing for meningitis in febrile well-appearing young infants with a positive urinalysis. *Pediatrics*. 2019;144(3):e20183979
- 4. Young BR, Nguyen THP, Alabaster A, Greenhow TL. The prevalence of bacterial meningitis in febrile infants 29-60 days with positive urinalysis. *Hosp Pediatr*. 2018;8(8):450-457
- 5. Use of Oral Antibiotics in Febrile Infants 29-60 days with positive UAs
- 6. Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. *Pediatrics*. 1999;104(1 Pt 1):79-86

CSF Values

1. Thomson J, Sucharew H, Cruz AT, et al. Cerebrospinal Fluid Reference Values for Young Infants Undergoing Lumbar Puncture. *Pediatrics*. 2018;141(3). doi:10.1542/peds.2017-3405

Disposition

Discharge from the hospital within 24-36 hours:

- 1. Aronson PL, Wang ME, Nigrovic LE, et al. Time to pathogen detection for non-ill versus ill-appearing infants ≤60 days old with bacteremia and meningitis. *Hosp Pediatr*. 2018;8(7):379-384
- 2. Biondi EA, Mischler M, Jerardi KE, et al. Blood culture time to positivity in febrile infants with bacteremia. *JAMA Pediatr.* 2014;168(9):844-849

Discharge from the emergency department with close follow-up:

- 1. Alpern ER, Kuppermann N, Blumberg S et al. Time to positive blood and cerebrospinal fluid cultures in febrile infants ≤60 days of age. *Hosp Pediatr*. 2020 Sep;10(9):719-727
- 2. Greenhow TL, Hung YY, Pantell RH. Management and outcomes of previously healthy, full-term, febrile infants ages 7 to 90 days. *Pediatrics*. 2016;138(6):e20160270
- 3. Mintegi S, Gomez B, Martinez-Virumbrales L, Morientes O, Benito J. Outpatient management of selected young febrile infants without antibiotics. *Arch Dis Child*. 2017 Mar;102(3):244-249
- 4. Pantell RH, Newman TB, Bernzweig J, et al. Management and outcomes of care of fever in early infancy. *JAMA*. 2004;291(10):1203-1212

Parent Engagement

1. Aronson PL, Politi MC, Schaeffer P, et al. Development of an app to facilitate communication and shared decision-making with parents of febrile infants ≤60 days old. *Acad Emerg Med.* 2021;28(1):46-59